Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus EP in extensive-stage small cell lung cancer (China, ECOG 0–2)
CTR20200951Phase 3Completed
- Sponsor
- MedImmune
- Start
- Aug 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in small cell lung cancer (SCLC), sponsored by MedImmune. Started Aug 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20200951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200951.